参考文献/References:
［1］刘萍. 中国大陆 13 年宫颈癌临床流行病学大数据评价 ［J］. 中国实用妇科与产科杂志, 2018, 34(1): 4145.
［2］Tsu V, Jerónimo J. Saving the world's women from cervical cancer［J］. New England Journal of Medicine, 2016, 374(26): 25092511.
［3］Meng J W, Song J H. Association between interleukin2, interleukin10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions ［J］. Oncology Letters, 2019, 18(5): 55435548.
［4］McLachlin C M. Human papillomavirus in cervical neoplasia: role, risk factors, and implications ［J］. Clinics in Laboratory Medicine, 2000, 20(2): 257270.
［5］Alves J J P, Fernandes T A A M, De Araujo J M G, et al. Th17 response in patients with cervical cancer ［J］. Oncology Letters, 2018, 16(5): 62156227.
［6］Barros M R, de Oliveira T H A, de Melo C M L, et al. Viral modulation of TLRs and cytokines and the related immunotherapies for HPVassociated cancers ［J］. Journal of Immunology Research, 2018, 2018：117.
［7］ValleMendiola A, GutiérrezHoya A, LagunasCruz M C, et al. Pleiotropic effects of IL2 on cancer: its role in cervical cancer ［J］. Mediators of Inflammation, 2016, 2016：111.
［8］Li B, Zhang L, Zhao J, et al. The value of cytokine levels in triage and risk prediction for women with persistent highrisk human papilloma virus infection of the cervix ［J］. Infectious Agents and Cancer, 2019, 14(1): 16.
［9］Zheng J J, Song J H, Yu C X, et al. Difference in vaginal microecology, local immunity and HPV infection among childbearingage women with different degrees of cervical lesions in Inner Mongolia ［J］. BMC Women's Health, 2019, 19(1): 18.
［10］徐愔烨. HPV L1 蛋白及 IL2 在宫颈组织中的表达及意义 ［D］. 浙江大学医学院, 2010: 12.
［11］赵书利, 李晨, 兰露莎, 等. 老年高危型人乳头瘤状病毒感染后宫颈微环境中细胞因子变化 ［J］. 中国老年学杂志, 2019 ，39(16): 40074009.
［12］刘易斯, 王敏, 陶陶. 宫颈组织中白介素2, 白介素4 在 HPV 感染不同类型宫颈病变中的表达 ［J］. 中国继续医学教育, 2017, 9(27): 5658.
［13］王燕，温先勇，杨梅，等. 持续高危 HPV 感染的宫颈病变患者免疫及其调节功能探讨 ［J］. 现代预防医学, 2019 ,46(9):16001603.
［14］张玲, 曲芃芃. HRHPV 持续感染宫颈局部 8 种细胞因子变化的研究 ［J］. 中国妇产科临床杂志, 2018, 19(1): 68.
［15］周平乐, 孙彬彬. 宫颈病变患者高危型 HPV 感染情况及其与血清炎性因子的关系 ［J］. 山东医药, 2015, 55(30): 4748.
［16］Song Z, Lin Y, Ye X, et al. Expression of IL1α and IL6 is associated with progression and prognosis of human cervical cancer ［J］. Medical Science Monitor:International Medical Journal of Experimental and Clinical Research, 2016, 22: 4475.
［17］Xu J, Ye Y, Zhang H, et al. Diagnostic and prognostic value of serum interleukin6 in colorectal cancer ［J］. Medicine, 2016, 95(2)：e 2502.
［18］Wang Q, Xue Y. Characterization of solid tumors induced by polycyclic aromatic hydrocarbons in mice［J］. Medical Science Monitor Basic Research, 2015, 21: 81.
［19］赵婧. 影响 HRHPV 感染及宫颈病变的相关因素分析［D］. 延安大学, 2019.
［20］谷倩云. IL6在宫颈上皮内瘤变和宫颈癌中的表达及意义［D］.山西医科大学, 2017.
［21］王燕翔，李或白，王丽伶，等.宫颈癌患者血清IL6、CA125、SCCA的表达水平及临床意义［J］. 疑难病杂志， 2019, 18 (5): 489492.
［22］金彦. III、IV期宫颈癌患者 5 年生存率和影响因素分析［J］. 现代实用医学， 2014, 26(6): 701703.
［23］Wei L H, Kuo M L, Chen C A, et al. Interleukin6 in cervical cancer: the relationship with vascular endothelial growth factor［J］. Gynecologic Oncology, 2001, 82(1): 4956.
［24］Wei L H, Kuo M L, Chen C A, et al. Interleukin6 promotes cervical tumor growth by VEGFdependent angiogenesis via a STAT3 pathway［J］. Oncogene, 2003, 22(10): 1517.
［25］Luan S, An Z, Bi S, et al. Interleukin 6 receptor (IL6R) was an independent prognostic factor in cervical cancer ［J］. Histology and Histopathology, 2018, 33(3): 269276.
［26］王秋兰, 张俊会. 宫颈癌中 HPV16 感染与 IL6 表达的关系［J］. 肿瘤防治研究, 2010，37(1): 7780.
［27］杨文静, 王璐. 血清鳞状细胞癌相关抗原联合 IL6, TGFβ 在宫颈癌中的诊断价值及临床意义［J］. 标记免疫分析与临床, 2017, 24(1): 7780.
［28］Park H, Li Z, Yang X O, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17［J］. Nature Immunology, 2005, 6(11): 1133.
［29］Harrington L E, Hatton R D, Mangan P R, et al. Interleukin 17producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages ［J］. Nature Immunology, 2005, 6(11): 1123.
［30］Alves J J P, Fernandes T A A M, De Araujo J M G, et al. Th17 response in patients with cervical cancer［J］. Oncology letters, 2018, 16(5): 62156227.
［31］Ye J, Livergood R S, Peng G. The role and regulation of human Th17 cells in tumor immunity［J］. The American Journal of Pathology, 2013, 182(1): 1020.
［32］武汉良，谭彩虹，张妤，等. IL1β、IL17的表达和HPV感染与宫颈癌的关系研究［J］. 现代诊断与治疗， 2018, 29(22): 36413642.
［33］Xue J S, Wang Y L, Chen C, et al. Effects of Th17 cells and IL17 in the progression of cervical carcinogenesis with high‐risk human papillomavirus infection［J］. Cancer Medicine, 2018, 7(2): 297306.
［34］Punt S, Fleuren G J, Kritikou E, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL17 is associated with poor prognosis in squamous cervical cancer［J］. Oncoimmunology, 2015, 4(1): e 984539.
［35］薛纪森, 朱华, 章圣辉, 等. Th17 细胞免疫应答对高危型人乳头瘤病毒感染宫颈疾病的影响［J］. 温州医科大学学报, 2017, 47(7): 504509.
［36］周萍, 冉晓敏. 人乳头瘤病毒感染宫颈病变患者外周血辅助性 T17 细胞, 调节性 T 细胞和炎症因子的变化及临床意义［J］. 中国妇幼保健, 2019, 34(6): 12421245.
［37］王瑞, 郭乐峰, 王昊. 宫颈癌患者外周血 Th22, Th17, IL17, IL22 表达与疾病进展的相关性分析 ［J］. 中国医学前沿杂志, 2018, 10(6): 192195.
［38］Feng M, Wang Y, Chen K, et al. IL17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NFκB signal pathway［J］. PLoS One, 2014, 9(9): e 108502.
［39］Feldmeyer L, Werner S, French L E, et al. Interleukin1, inflammasomes and the skin ［J］. European Journal of Cell Biology, 2010, 89(9): 638644.
［40］León X, Bothe C, García J, et al. Expression of IL1α correlates with distant metastasis in patients with head and neck squamous cell carcinoma ［J］. Oncotarget, 2015, 6(35): 37398.
［41］Brooks D G, Trifilo M J, Edelmann K H, et al. Interleukin10 determines viral clearance or persistence in vivo ［J］. Nature Medicine, 2006, 12(11): 1301.
［42］BermudezMorales V H, Gutiérrez L X, AlcocerGonzález J M, et al. Correlation between IL10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape ［J］. Cancer Investigation, 2008, 26(10): 10371043.
［43］Wang S, An W, Yao Y, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells ［J］. Journal of Cancer, 2015, 6(10): 962
相似文献/References:
[1]彭丽霞,张娟.阴道镜下定位活检在宫颈病变诊断中的价值[J].中国计划生育和妇产科,2009,(06):0.
PENG Li-xia,ZHANG Juan.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(6):0.
[2]冯学宇,乔银川,王好宁,等.823例宫颈癌机会性筛查结果分析[J].中国计划生育和妇产科,2010,(01):0.
FENG Xue-yu,QIAO Yin-chuan,WANG Hao-ning ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[3]刘佳汭.保留盆腔自主神经的宫颈癌根治性手术[J].中国计划生育和妇产科,2010,(02):0.
[4]甘玉杰,熊小英,蔡春芳,等.血清SCCA、CA125、CA19-9与高危型人乳头状瘤病毒在宫颈癌及癌前病变中的表达及意义[J].中国计划生育和妇产科,2010,(04):0.
GAN Yu-jie,XIONG Xiao-ying,CAI Chun-fang,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[5]陶凤喜,王海新.HPV感染与宫颈病变的关系分析[J].中国计划生育和妇产科,2010,(05):0.
TAO Feng-xi,WANG Hai-xin.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[6]罗海全,李明,刘兴会,等.宫颈病变锥形切除术后妊娠不良结局相关因素分析[J].中国计划生育和妇产科,2010,(05):0.
LUO Hai-quan,LI Ming,LIU Xing-hui ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[7]肖春燕,陈桂珍,铁木帅龙,等.325例宫颈病变阴道镜检查结果分析[J].中国计划生育和妇产科,2010,(05):0.
XIAO Chun-yan,CHEN Gui-zhen,TIEMU-Shuailong.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[8]普俊梅,文勇,黄予,等.高危型HPV DNA检测在宫颈病变筛查和宫颈癌预防中的价值[J].中国计划生育和妇产科,2012,(04):0.
PU Jun-mei,WEN Yong,HUANG Yu,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[9]孟跃进,顾晓荔.阴道镜宫颈病变活体组织检查及活体组织检查后治疗问题[J].中国计划生育和妇产科,2013,(01):0.
MENG Yue-jin,GU Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[10]张宏伟,隋龙.液基细胞学技术在宫颈病变筛查的应用现状及不足[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Hong-wei,SUI Long Medical Center of Diagnostics & Treat for Cervical Disease,Gynaecology and Obstetrics Hospital of Fudan University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[11]安红梅,张雯,邓继红,等.昆明地区高危HPV病毒载量与宫颈病变和宫颈癌相关性[J].中国计划生育和妇产科,2013,(03):0.
AN Hong - mei,ZHANG Wen,DENG Ji - hong *,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[12]聂明月,叶红*.宫颈病变中人乳头瘤病毒相关微小RNA的研究进展[J].中国计划生育和妇产科,2020,(6):12.